{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:53:07Z","timestamp":1770821587302,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006520","name":"Edwards Lifesciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006520","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32HL129948"],"award-info":[{"award-number":["T32HL129948"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcardioanesthesia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1053\/j.jvca.2021.03.004","type":"journal-article","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T06:39:06Z","timestamp":1615099146000},"page":"1709-1714","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bivalirudin as a Systemic Anticoagulant and Flush Solution Additive for Sequential Mitral and Tricuspid Valve Percutaneous Edge-to-Edge Repair in a Patient With Heparin-Induced Thrombocytopenia"],"prefix":"10.1053","volume":"36","author":[{"given":"Zachary","family":"Colbaugh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Thomas Evans","family":"Watts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa I.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3856-6419","authenticated-orcid":false,"given":"Dylan R.","family":"Addis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.jvca.2021.03.004_bib0001","unstructured":"US Food and Drug Administration. Premarket approval (PMA). Available at: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm?id=P100009. Accesssed March 19, 2021."},{"key":"10.1053\/j.jvca.2021.03.004_bib0002","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCINTERVENTIONS.109.884478","article-title":"Anticoagulant therapy for percutaneous coronary intervention","volume":"3","author":"Rao","year":"2010","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1053\/j.jvca.2021.03.004_bib0003","doi-asserted-by":"crossref","first-page":"e02","DOI":"10.15420\/icr.2019.24","article-title":"Anticoagulation after transcatheter aortic valve implantation: Current status","volume":"15","author":"Greco","year":"2020","journal-title":"Interv Cardiol"},{"key":"10.1053\/j.jvca.2021.03.004_bib0004","unstructured":"US Food and Drug Administration. Heparin sodium, for intravenous use: Highlights of presribing information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/017029s140lbl.pdf. Accesssed March 19, 2021."},{"key":"10.1053\/j.jvca.2021.03.004_bib0005","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1182\/blood-2016-11-709873","article-title":"Heparin-induced thrombocytopenia","volume":"129","author":"Arepally","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.jvca.2021.03.004_bib0006","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2141.2006.06018.x","article-title":"The management of heparin-induced thrombocytopenia","volume":"133","author":"Keeling","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1053\/j.jvca.2021.03.004_bib0007","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1056\/NEJM200008173430718","article-title":"Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia","volume":"343","author":"Potzsch","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2021.03.004_bib0008","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-199222050-00003","article-title":"Heparin pharmacokinetics and pharmacodynamics","volume":"22","author":"Kandrotas","year":"1992","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.jvca.2021.03.004_bib0009","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1213\/ANE.0b013e3181c3c1cd","article-title":"Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia","volume":"110","author":"Welsby","year":"2010","journal-title":"Anesth Analg"},{"key":"10.1053\/j.jvca.2021.03.004_bib0010","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/jca.20289","article-title":"Use of plasma exchange in patients with heparin-induced thrombocytopenia: A report of 2 cases and a review of the literature","volume":"26","author":"Jaben","year":"2011","journal-title":"J Clin Apher"},{"key":"10.1053\/j.jvca.2021.03.004_bib0011","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/17474086.2019.1636645","article-title":"High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: A review","volume":"12","author":"Warkentin","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"10.1053\/j.jvca.2021.03.004_bib0012","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1213\/00000539-198605000-00018","article-title":"Heparin-associated thrombocytopenia: Alternative managements","volume":"65","author":"Vender","year":"1986","journal-title":"Anesth Analg"},{"key":"10.1053\/j.jvca.2021.03.004_bib0013","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.chest.2017.05.043","article-title":"Intravenous immunoglobulin for heparin-induced thrombocytopenia","volume":"152","author":"Ibrahim","year":"2017","journal-title":"Chest"},{"key":"10.1053\/j.jvca.2021.03.004_bib0014","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMc1801799","article-title":"Intravenous immune globulin to prevent heparin-induced thrombocytopenia","volume":"378","author":"Warkentin","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2021.03.004_bib0015","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","article-title":"Transcatheter mitral-valve repair in patients with heart failure","volume":"379","author":"Stone","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2021.03.004_bib0016","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","article-title":"Transcatheter mitral-valve repair in patients with heart failure [supplemental material]","volume":"379","author":"Stone","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2021.03.004_bib0017","unstructured":"US Food and Drug Administration. ANGIOMAX\u00ae (bivalirudin) for injection, for intravenous use: Highlights of prescribing information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/020873s036lbl.pdf. Accessed March 19, 2021."},{"key":"10.1053\/j.jvca.2021.03.004_bib0018","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2021.03.004_bib0019","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2021.03.004_bib0020","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4244\/EIJV10I3A54","article-title":"Effect of bivalirudin on aortic valve intervention outcomes study: A two-centre registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty","volume":"10","author":"Kini","year":"2014","journal-title":"EuroIntervention"},{"key":"10.1053\/j.jvca.2021.03.004_bib0021","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1016\/j.jacc.2015.10.003","article-title":"Bivalirudin versus heparin anticoagulation in transcatheter aortic valve replacement: The randomized BRAVO-3 trial","volume":"66","author":"Dangas","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2021.03.004_bib0022","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/joic.12428","article-title":"Bivalirudin versus heparin in patients undergoing percutaneous transcatheter aortic valve interventions: A systematic review and meta-analysis","volume":"30","author":"Villablanca","year":"2017","journal-title":"J Interv Cardiol"},{"key":"10.1053\/j.jvca.2021.03.004_bib0023","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1097\/MAT.0000000000001126","article-title":"Anticoagulation of Impella with a bivalirudin purge solution","volume":"66","author":"Szymanski","year":"2020","journal-title":"ASAIO J"},{"key":"10.1053\/j.jvca.2021.03.004_bib0024","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/3791307","article-title":"Survey of anticoagulation practices with the Impella percutaneous ventricular assist device at high-volume centers","volume":"2019","author":"Reed","year":"2019","journal-title":"J Interv Cardiol"},{"key":"10.1053\/j.jvca.2021.03.004_bib0025","first-page":"998","article-title":"Bivalirudin vs heparin in patients who undergo transcatheter aortic valve implantation","volume":"31","author":"Lange","year":"2015","journal-title":"Can J Cardiol"},{"key":"10.1053\/j.jvca.2021.03.004_bib0026","first-page":"158","article-title":"Successful anticoagulation using argatroban during transcatheter aortic valve implantation in a patient with heparin-induced thrombocytopenia","volume":"7","author":"Naganuma","year":"2016","journal-title":"AA Case Rep"},{"key":"10.1053\/j.jvca.2021.03.004_bib0027","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1023\/A:1012919404290","article-title":"A synopsis of the clinical uses of argatroban","volume":"12","author":"Moledina","year":"2001","journal-title":"J Thromb Thrombolysis"},{"key":"10.1053\/j.jvca.2021.03.004_bib0028","unstructured":"US Food and Drug Administration. Argatroban injection in 0.9% sodium chloride, for intravenous infusion only: Highlights of prescribing information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/022485lbl.pdf. Accessed March 19, 2021."},{"key":"10.1053\/j.jvca.2021.03.004_bib0029","article-title":"Argatroban versus bivalirudin in the treatment of suspected or confirmed heparin-induced thrombocytopenia","author":"Duewell","year":"2019","journal-title":"J Pharm Pract"},{"key":"10.1053\/j.jvca.2021.03.004_bib0030","unstructured":"US Food and Drug Administration. Bivalirudin clinical BPCA: Angiomax\u00ae injection. Available at: https:\/\/www.fda.gov\/media\/78215\/download. Accessed March 19, 2021."},{"key":"10.1053\/j.jvca.2021.03.004_bib0031","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1051\/ject\/200537364","article-title":"Sensitivity of a modified ACT test to levels of bivalirudin used during cardiac surgery","volume":"37","author":"Zucker","year":"2005","journal-title":"J Extra Corpor Technol"},{"key":"10.1053\/j.jvca.2021.03.004_bib0032","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1055\/s-0038-1675586","article-title":"Antithrombotic management during percutaneous mitral valve repair with the Mitraclip system in a patient with heparin-induced thrombocytopenia","volume":"2","author":"Saia","year":"2018","journal-title":"TH Open"}],"container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077021002068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077021002068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T15:10:36Z","timestamp":1762355436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053077021002068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1053077021002068"],"URL":"https:\/\/doi.org\/10.1053\/j.jvca.2021.03.004","relation":{},"ISSN":["1053-0770"],"issn-type":[{"value":"1053-0770","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bivalirudin as a Systemic Anticoagulant and Flush Solution Additive for Sequential Mitral and Tricuspid Valve Percutaneous Edge-to-Edge Repair in a Patient With Heparin-Induced Thrombocytopenia","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiothoracic and Vascular Anesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.jvca.2021.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}